Mitigating Radiation-Induced Cognitive Toxicity in Brain Metastases: More Questions Than Answers

dc.contributor.authorSimó, Marta
dc.contributor.authorRodríguez Fornells, Antoni
dc.contributor.authorNavarro, Valentín
dc.contributor.authorNavarro Martín, Arturo
dc.contributor.authorNadal, Ernest
dc.contributor.authorBruna, Jordi
dc.date.accessioned2024-10-14T13:37:21Z
dc.date.available2024-10-14T13:37:21Z
dc.date.issued2024-01-01
dc.date.updated2024-10-04T10:21:59Z
dc.description.abstractThe emergence of advanced systemic therapies added to the use of cranial radiation techniques has significantly improved outcomes for cancer patients with multiple brain metastases (BM), leading to a considerable increase in long-term survivors. In this context, the rise of radiation-induced cognitive toxicity (RICT) has become increasingly relevant. In this critical narrative review, we address the controversies arising from clinical trials aimed at mitigating RICT. We thoroughly examine interventions such as memantine, hippocampal avoidance irradiation during BM treatment or in a prophylactic setting, and the assessment of cognitive safety in stereotactic radiosurgery (SRS). Our focus extends to recent neuroscience research findings, emphasizing the importance of preserving not only the hippocampal cortex but also other cortical regions involved in neural dynamic networks and their intricate role in encoding new memories. Despite treatment advancements, effectively managing patients with multiple BM and determining the optimal timing and integration of radiation and systemic treatments remain areas requiring further elucidation. Future trials are required to delineate optimal indications and ensure SRS safety. Additionally, the impact of new systemic therapies and the potential effects of delaying irradiation on cognitive functioning also need to be addressed. Inclusive trial designs, encompassing patients with multiple BM and accounting for diverse treatment scenarios, are essential for advancing effective strategies in managing RICT and the treatment of BM patients.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2632-2498
dc.identifier.pmid39247496
dc.identifier.urihttps://hdl.handle.net/2445/215757
dc.language.isoeng
dc.publisherOxford University Press (OUP)
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1093/noajnl/vdae137
dc.relation.ispartofNeuro-Oncology Advances, 2024, vol. 6, num. 1
dc.relation.urihttps://doi.org/10.1093/noajnl/vdae137
dc.rightscc by-nc (c) Simó, Marta et al, 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationRadioteràpia
dc.subject.classificationToxicitat dels medicaments
dc.subject.otherRadiotherapy
dc.subject.otherDrug toxicity
dc.titleMitigating Radiation-Induced Cognitive Toxicity in Brain Metastases: More Questions Than Answers
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
vdae137.pdf
Mida:
440.81 KB
Format:
Adobe Portable Document Format